Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Trial Profile

Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Hereditary haemorrhagic telangiectasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 27 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 23 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top